Got RA? Don't Delay!

Published Online: Monday, July 1, 2002

When it comes to beginning treatment for rheumatoid arthritis, minutes and seconds may not count, but weeks and months surely do.

In a 3-year study at the University Hospital of Vienna and at Lainz Hospital in Austria, researchers found that there is a definite "window of opportunity" for successful treatment.

The study compared patients with very early disease who had waited an average of 3 months before being started on drugs to a group who had waited 20 months to start therapy.

After just 3 months of treatment, patients with early therapy were doing better than those who had waited longer. At the end of the study, 70% of patients in the early-treatment group showed a 20% improvement in disease symptoms. Meanwhile, only 40% of those in the later-treatment group improved.

The researchers concluded that introducing disease-modifying drugs very early "seems highly beneficial in [rheumatoid arthritis] compared with even relatively short delay."

Latest Articles
James Schiffer, RPh, associate at Allegaert Berger & Vogel LLC, discusses some tips for pharmacists who are facing a Drug Enforcement Administration audit.
Carlos Aquino, founder and president of PharmaDiversion LLC, talks about the importance of the Drug Enforcement Administration's (DEA) diversion website.
Having trouble getting your hands on FluMist?
Novartis is paying $390 million to settle charges that it paid kickbacks to pharmacies to encourage drug sales.
Latest Issues